Zinplava is a human monoclonal antibody indicated to reduce recurrence of *Clostridioides difficile* infection (CDI) in patients 18 years and older who are receiving standard of care antibacterial treatment for CDI and are at high risk for CDI recurrence. Zinplava acts by binding to *C. difficile* toxin B and neutralizing its effects. Zinplava is administered as a one-time 60-minute intravenous infusion during antibacterial treatment for CDI.

Zinplava (bezlotoxumab) will be considered for coverage when the following criteria are met:

**Reduce recurrence of *Clostridioides difficile* infection (CDI)**

For **initial** authorization:
1. Member is at least 18 years of age; AND
2. Medication is prescribed by or in consultation with a gastroenterologist or infectious disease specialist; AND
3. Member has documentation of 3 or more loose stools or liquid stools within 24 hours; AND
4. Member has a positive stool test for the presence of *Clostridioides difficile* within the past 7 days; AND
5. Member is receiving standard of care antibacterial drug treatment for CDI (i.e., vancomycin, fidaxomicin, or metronidazole); AND
6. Member will receive Zinplava (bezlotoxumab) before completing antibacterial treatment for CDI; AND
7. Member meets one or more of the following criteria:
   a. Member has documentation of one or more CDI episodes within the last 6 months in addition to the current episode
   b. Member is ≥ 65 years of age
   c. Member is immunocompromised (i.e., history or use of immunosuppressive therapy)
   d. Member has documentation of severe CDI (i.e., WBC > 15,000 cells/mL or serum creatinine ≥ 1.5 mg/dL); AND
8. **Dosage allowed/Quantity limit:** Administer a single dose of 10 mg/kg during antibacterial treatment for CDI.

*If all the above requirements are met, one dose of the medication will be approved.*

For **reauthorization**:
1. Medication will not be reauthorized.

CareSource considers Zinplava (bezlotoxumab) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.
OH-MED-P-366685

<table>
<thead>
<tr>
<th>DATE</th>
<th>ACTION/DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/25/2023</td>
<td>New policy for Zinplava created.</td>
</tr>
</tbody>
</table>

References:


Effective date: 01/01/2024
Revised date: 04/25/2023